Lou Gehrig’s Disease Drug Failure Crushes Biogen Idec
Biogen Idec Inc. (NASDAQ: BIIB) is living up to why we just said it is now an overvalued biotech stock for 2013. Biogen Idec and the other biotech giants had risen perhaps too ...Read Full Story »

